Loading
This study tests a PARP inhibitor; the registry reports that it is recruiting.
The registry lists NCT05740956 as recruiting, last updated 2025-06-05. Enrolment is 318 planned participants, an estimate. Interventions: HS-10502. Primary measures include Maximum tolerated dose (MTD) of HS-10502（Stage 1）; Maximum applicable dose (MAD) of HS-10502（Stage 1）. No results are posted in the registry; this does not exclude separate publications.
Shares HS-10502, PARP, Ovarian cancer, Breast cancer (all types).
Shares PARP, Ovarian cancer, Breast cancer (all types), Pancreatic ductal adenocarcinoma.
Shares PARP, Ovarian cancer, Breast cancer (all types), Pancreatic ductal adenocarcinoma.
Shares PARP, Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer.
Shares PARP, Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer.
Shares PARP, Ovarian cancer, Breast cancer (all types).
Shares PARP, Ovarian cancer, Prostate cancer.
Shares PARP, Breast cancer (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/